查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049622

生技藥品市場規模、佔有率、趨勢和預測：按來源、產品、疾病、生產方法和地區分類，2026-2034年

Biologics Market Size, Share, Trends and Forecast by Source, Product, Disease, Manufacturing, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 138 Pages | 商品交期: 2-3個工作天內

價格

2025年全球生物製藥市場規模為4,055億美元。展望未來，IMARC Group預測，該市場將以7.30%的複合年成長率從2026年成長至2034年，到2034年達到7,793億美元。目前，北美市場佔據主導地位，預計2025年市佔率將超過44.8%。推動生物製藥市場成長的因素包括：慢性病盛行率的上升，導致對更有效治療方法的需求增加；持續的技術進步促進了更具標靶性的治療方法的開發；以及先進藥物遞送系統的出現。

在對創新治療方法的需求不斷成長和生物技術進步的推動下，全球生物製劑市場正以驚人的速度擴張。生物製劑是生物來源的產品，包括單株抗體、疫苗、細胞和基因療法以及重組蛋白。所有這些治療方法都透過為糖尿病、癌症和自體免疫疾病等慢性疾病提供標靶有效的治療方法，正在改變醫療保健產業。慢性疾病盛行率的上升和人口老化是推動生物製藥應用的重要因素。此外，研發投入的增加正在加速下一代生物製藥（包括提供經濟實惠替代方案的生物相似藥）的上市。監管和核准的支持也為生物製藥市場的成長鋪平了道路。

美國正崛起為生物製藥的重要區域市場。推動該市場成長的因素包括：對創新治療方法的需求不斷成長、生物技術的進步以及對個人化醫療日益成長的興趣。癌症、自體免疫疾病和糖尿病等慢性病的高發生率也促進了對生物製藥的需求。生物相似藥的日益普及以及生物製藥的使用量超過傳統藥物的趨勢進一步推動了市場成長。根據生物製藥市場分析報告，製藥公司研發投入的持續成長，以及政府有利政策的支持，正在推動市場成長。此外，醫療基礎設施和報銷政策的改善也使生物製藥更容易獲得。同時，對精準醫療的關注以及生物製藥的未來潛力表明，美國市場將繼續穩定成長。

生物製藥市場趨勢：

標靶治療的持續創新

在生物製藥市場中，針對複雜分子的關鍵趨勢之一是標靶治療的持續創新。標靶治療方法旨在僅作用於導致疾病的特定細胞或分子，從而增強療效並最大限度地減少副作用。對於癌症和自體免疫疾病等嚴重，標靶治療提供了一種新型有效的治療手段。根據歐洲腫瘤內科學會 (ESMO) 的數據，2006 年至 2020 年間，共有 51 種藥物獲準 72 項核准，這些藥物針對 18 種癌症的 36 種基因組相關適應症。這使得符合基因組標靶治療的患者比例從 5.13% 提高到 13.60%，有效率從 2.73% 提高到 7.04%。同時，對於利用基因組資訊的治療方法，符合條件的患者比例從 10.70% 提高到 27.30%，有效率從 3.33% 提高到 11.10%。例如，2024年3月，加州理工學院的研究人員開發了一種超音波活化藥物遞送系統，該系統專注於癌症治療，同時最大限度地減少副作用。這項技術透過氣體囊泡和機械力敏分子的結合來活化藥物，從而精準地減少對健康組織的損傷。同樣，2024年3月，《自然醫學》雜誌發表了一篇關於鞘內注射自體二價嵌合體抗原受體T細胞（CAR-T細胞）治療復發性膠質母細胞瘤（rGBM）患者的報告。此治療方法同時針對兩種蛋白質：表皮生長因子受體（EGFR）和白細胞介素-13受體α2（IL13Ra2）。這些T細胞能夠標靶抑制高侵襲性腦腫瘤的生長。大規模的科學研究已經從分子層面闡明了疾病機制，從而開發出比傳統療法更有效、更毒性更小的特異性治療方法。預計這一趨勢將增加對研發的投入，並提高人們對個人化醫療的關注。這些治療方法的引入及其後續成功將顯著增加對複雜分子的需求，並將成為市場發展的關鍵催化劑。人們越來越傾向於選擇療效更高、毒性更低的精準療法，這正在加速市場對標靶生技藥品的需求。

先進藥物輸送系統的出現

藥物遞送系統在醫療保健領域的重要性日益凸顯，它往往影響複雜分子療法的療效以及患者的用藥依從性。該領域的創新涵蓋了從緩釋機製到基於奈米技術的遞送系統等許多方面。報告顯示，預計2024年，全球整體奈米技術市場規模將達到1,250億美元，它將透過實現標靶藥物遞送、加速癌症治療以及增強生物分子的穩定性和療效，徹底改變生物製藥產業。例如，北卡羅來納大學的研究人員於2024年1月發布了時空按需貼片（SOP），這是一種類似OK繃的無線藥物遞送系統。此無線貼片可以接收來自電腦或智慧型手機的指令，從而實現對基於微針的藥物遞送的定時和控制。這大大簡化了患者遵循治療方案的過程，從而在臨床環境中改善了治療效果。未來，這種新型遞送系統有望以每週或每月一次的給藥方式取代每日注射，這將大大提高患者的便利性，並增強他們堅持治療的動機。目前，大量投資正用於研發，旨在最大限度地發揮複雜分子的治療效果。此類藥物遞送系統的研究進展提升了生物製藥市場的價值，並大大拓展了成長機遇，以滿足對更高效、更人性化的替代治療方法的巨大需求。這種創新主導的環境反映了對符合以患者為中心的護理模式的給藥方法的日益成長的需求。

法規的變更和協調

醫療保健產業的公司一直面臨著極其複雜且充滿挑戰的法規環境。然而，隨著監管協調的推進，情況正變得越來越清晰。 2023年7月，美國食品藥物管理局（FDA）與國際人用藥品註冊技術協調會議（ICH）合作發布了題為「良好臨床實踐（GCP）E6（R3）」的指導草案，指出這些指南旨在「提供統一的標準，促進ICH成員國和地區之間臨床數據的相互認可，從而推動設計更具創新性和效率的臨床試驗」。各國統一或相互認可的核准流程顯著降低了市場准入門檻，這意味著新產品和現有產品現在可以比以往更快地惠及更廣泛的患者群體。創新治療方法的快速普及以及這些療法顯著擴大的地域覆蓋範圍意義重大。這種監管實踐的有利協調，加快了核准並擴大了市場進入，正在推動複雜的全球生物製藥市場持續成長，並為生物製藥市場帶來了光明的前景。此外，這些簡化監管的舉措正在鼓勵全球製造商更積極地投資跨境生物製藥的研發。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球生技藥品市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依來源

  • 微生物
  • 哺乳動物
  • 其他

第7章 市場區隔：依產品分類

  • 單株抗體
  • 疫苗
  • 重組蛋白
  • 反義療法、RNA干擾療法與分子療法
  • 其他

第8章 市場區隔：依疾病分類

  • 腫瘤學
  • 免疫系統疾病
  • 心血管疾病
  • 血液疾病
  • 其他

第9章 市場區隔：依製造業分類

  • 外包
  • 內部

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
Product Code: SR112026A3883

The global biologics market size was valued at USD 405.5 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 779.3 Billion by 2034, exhibiting a CAGR of 7.30% from 2026-2034. North America currently dominates the market, holding a market share of over 44.8% in 2025. The rising prevalence of chronic diseases, which necessitate more effective treatment options, continuous technological advancements facilitating the development of increasingly targeted therapies, and the emergence of advanced drug delivery systems are some of the factors catalyzing the biologics market share.

The global biologics market is expanding at a very fast pace due to the increasing demand for innovative therapies and biotechnology advancement. Biologics are products that derive from living organisms, and such products include monoclonal antibodies, vaccines, cell and gene therapies, and recombinant proteins. All of these therapies are altering health care since they bring focused, effective treatments for chronic diseases such as diabetes, cancer and autoimmune diseases. The increasing incidence of chronic diseases, along with the geriatric population, is highly driving the uptake of biologics. Furthermore, investments in research and development are fast-tracking the launch of next-generation biologics, including biosimilars , which provide cost-effective alternatives. Support from regulations and approvals has also paved the way for the biologics market growth.

The United States has emerged as a key regional market for biologics. The market is fueled by growing demand for innovative therapies, advancements in biotechnology, and increasingly interested in personalized medicine. The high incidence of chronic conditions, such as cancer, autoimmunity disorders, and diabetes, is driving the demand for biological treatments. The further expansion of biosimilars and the trend toward more use of biologic medicines over traditional pharmaceuticals is fueling further market growth. As per the biologics market analysis report, steadily growing investment research and development by pharmaceutical companies in support of favorable government policies promote growth in the market. Moreover, improvement in infrastructure for healthcare and reimbursement policy further enhances the availability of biological drugs. Further, a focus on precision medicine and the future of biologics is going to help the U.S. market grow steadily.

BIOLOGICS MARKET TRENDS:

Continuous innovations in targeted therapies

One of the significant biologics market trends for complex molecules is the continuous innovation in targeted therapies. These are therapies designed to specifically act on certain cells or molecules responsible for disease, thus increasing treatment effectiveness while minimizing side effects. Given the critical nature of diseases like cancer and autoimmune disorders, targeted therapies offer a novel and effective avenue for treatment. According to the European Society for Medical Oncology, between 2006 and 2020, there were 72 approvals for 51 drugs targeting 36 genomic indications across 18 types of cancer, which increased eligibility for genome-targeted therapies from 5. 13% to 13. 60% and increased response rates from 2. 73% to 7. 04%. Meanwhile, genome-informed therapies increased eligibility from 10. 70% to 27. 30% and response rates improved from 3. 33% to 11. 10%. For example, in March 2024, Caltech researchers created an ultrasound-activated drug-delivery system that focused on cancer treatment with minimum side effects. This technique combines gas vesicles and mechanophores to activate drugs, thereby reducing harm to healthy tissues precisely. Similarly, Nature Medicine released its report in March 2024 on the results of patients with recurrent glioblastoma (rGBM) treated intrathecally with bivalent chimeric antigen receptor T-cells, being autologous, with dual targeting of two proteins: epidermal growth factor receptor (EGFR), interleukin-13 receptor alpha 2 (IL13Ra2). These targeted T-cells against aggressive brain tumor growth end. Science research in large scales has been able to reveal mechanisms of diseases at the molecular level, and thus a treatment approach has been provided with specialized therapies that are much more effective and less toxic than traditional approaches. This trend is likely to see increased investments in research and development, along with a heightened focus on personalized medicine. Their introduction and subsequent success can significantly increase the demand for complex molecules, thereby acting as a critical catalyst for the market. The rising preference for precision treatments that offer higher efficacy and lower toxicity is accelerating market demand for targeted biologics.

Emergence of advanced drug delivery systems

Drug delivery systems have become increasingly important in healthcare, often determining the efficacy and patient compliance for complex molecular treatments. Innovation in this field takes many forms, from controlled-release mechanisms to nanotechnology-based delivery systems. According to reports, nanotechnology is expected to cross USD 125 Billion worldwide by 2024, which transforms biologics by facilitating targeted drug delivery, boosting cancer therapies, and increasing the stability and effectiveness of biomolecules. An example includes scientists from the University of North Carolina, who, in January 2024, launched the Spatiotemporal On-Demand Patch SOP, a wireless drug delivery system that resembles a band-aid. The wireless patch can receive commands from the computer or smartphone, where its delivery can be scheduled and controlled on the microneedle. This will allow a patient to follow the plan for their treatment much easier, leading to better outcomes in clinical practice. New delivery systems might eventually replace daily injections with a weekly or even a monthly dose, significantly increasing patient convenience and willingness to stay on treatment. Major investments are pouring into their research and development with the intention of maximizing the therapeutic efficiency of complex molecules. Such research in drug delivery systems advances significantly contribute to the biologics market value and opportunities for growth in satisfying a huge demand for more efficient, patient-friendly therapeutic alternatives. This innovation-driven environment reflects growing demand for delivery methods that align with patient-centric care models.

Regulatory changes and harmonization

Companies in the healthcare industry have had to grapple with a very difficult, labyrinthine regulatory environment. However, regulatory harmonization is making the scenario increasingly straightforward. The draft guidance of July 2023 from the US Food and Drug Administration, titled "Good Clinical Practice (GCP) E6(R3)", in cooperation with the International Council for Harmonisation (ICH), says it has been put in place "to provide a unified standard to facilitate mutual acceptance of clinical data between ICH member countries and regions in order to enhance more innovative and efficient design of clinical trials.". Reduced substantially, market entry barriers through unified or mutually recognized approval processes across different countries mean new and existing products can now easily reach a much wider patient base much sooner than they previously could. The rapid rollout of innovative therapies to patients and their significant geographic expansion has significant implications. This favorable alignment of regulatory practices, which expedites approval and expands market access, is driving ongoing growth in the global market for complex biologics molecules, thereby creating a positive biologics market outlook. These regulatory streamlining efforts are also encouraging global manufacturers to invest more aggressively in cross-border biologics development.

BIOLOGICS INDUSTRY SEGMENTATION:

Analysis by Source:

  • Microbial
  • Mammalian
  • Others

The microbial sources account for a majority share of 58.5% driven mainly by their cost-effectiveness, scalability, and high productivity in biologics manufacture. Microorganisms such as E. coli and yeast are very widespread to produce recombinant proteins, enzymes, and vaccines because they produce at very fast growth rates and because of simpler genetic manipulation. The manufacture of biologics involving minimal post-translational modification is very good with the system, and therefore, they dominate insulin, growth hormones, and certain therapeutic enzymes. Advances in the technological aspects of fermentation systems and bioprocessing techniques have further increased yield and efficiency, thus making microbial platforms even more attractive. Increasing demand for biosimilars and the trend of precision medicine continue to fuel investment in microbial technologies. Pharmaceutical companies also prefer microbial systems as they help them meet regulatory compliance while lowering production costs. These factors will ensure the continued dominance of microbial platforms in biologics manufacturing.

Analysis by Product:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi, and Molecular Therapy
  • Others

Monoclonal antibodies represent the largest segment with a share of 66.7% due to their crucial role in cancer, autoimmune diseases, and infectious disorders. The accuracy in the specificity of targeting antigens has placed them in a position as indispensable in personalized medicine. New areas of improvement in antibody engineering include bispecific antibodies and antibody-drug conjugates, which improve the efficacy of the therapeutic products. More investments in R&D have accelerated the regulatory approvals of these products, and they are increasingly being applied in clinical practice. The growing adoption of biosimilar monoclonal antibodies offers cost-effective solutions, widening their accessibility and further fueling market expansion. With ongoing innovation and the rising prevalence of chronic diseases, monoclonal antibodies remain a cornerstone of biologics development and commercialization, ensuring sustained growth.

Analysis by Disease:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

The oncology segment holds the largest share of 28.7%, supported by a global rise in cancer prevalence and the increasing adoption of targeted therapies. Advances in biologic products such as monoclonal antibodies, checkpoint inhibitors, and cell-based therapies offer improved survival advantages and quality of life as a part of cancer care. Investment in precision medicines and innovative developments in immuno-therapies also augment growth in this space. Further regulatory approval of new biologic products for varied types of cancers drives demand and supports growth in this market. As biologics demonstrate efficacy in managing and perhaps even curing cancers, their application within oncology remains on track, making it the most profitable segment in the market for biologics.

Analysis by Manufacturing:

  • Outsourced
  • In-House

In-house manufacturing leads the market with an 84.8% share, driven by the need to have greater control over production processes, intellectual property protection, and regulatory standards that are quite stringent. Companies using the in-house capacity can directly control quality assurance, respond quicker to production problems, and maintain integration with internal R&D teams. This also contributes to cost optimization in the long run by eliminating dependency on other partners. Such capability to streamline operations with proprietary knowledge, especially about high-value biologics, gives the advantage to in-house manufacturing. More importantly, modular and continuous manufacturing technologies have advanced with which companies have developed means to enhance scalability as well as efficiency, where different production demands can be met accordingly, but they do not have any external dependence on partners.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America held the highest share in 2025, with over 44.8%. North America dominates the market due to its developed healthcare infrastructure and increased investments in biopharmaceutical research. It contains numerous top biopharmaceutical companies and research organizations. Such innovation by various entities in the region creates an optimistic outlook for the market. Favorable regulatory support in the form of fast-track approvals for biologics and various financial incentives for extensive research and development activities are also contributing to the market growth. Furthermore, increasing patient awareness and willingness to adopt new therapies are further fueling the demand for biologics in North America. The U.S. also constitutes the biggest market in the region, primarily due to high healthcare spending, broad insurance coverage, and increasing chronic and lifestyle-related diseases.

Advanced demand for biologic therapies, accelerating healthcare, and improving infrastructure for healthcare drive the Asia Pacific biologics market. The increasing prevalence of chronic diseases coupled with an increased awareness about, and affordability of, biologics is promoting growth in the market. Government incentives to develop biosimilars are also driving market growth and have surged healthcare expenditure in the nations of China and India. A huge patient population and increasing research and development are two of the primary drivers of this market growth in the region.

In Europe, a well-developed healthcare system with higher accessibility toward advanced biologic treatment enhances the market growth for biologics. A high rate of incidence of autoimmune diseases, cancer, and other chronic conditions stimulates the need for biologics. Governments' support with positive regulation sets an impetus to accept biosimilars. The region's focus on research and innovation with a strong healthcare infrastructure provides the right environment to grow in biologics. In addition, increased expenditure on healthcare, as well as collaborative efforts between the public and private sectors, contribute to the momentum of this market.

In Latin America, better access to healthcare is fueling the growth of biologics. The region is also witnessing increased investments in the healthcare sector and a greater prevalence of chronic diseases. Affordability and access to biologics are improving through the efforts of governments, thereby increasing demand. Biosimilar adoption is also increasing along with regional initiatives that help cut drug costs. Brazil, Mexico, and Argentina are some of the major contributors to this growth due to increasing awareness about biologics and the expansion of healthcare markets, which attracts investments from multinational pharmaceutical companies.

The biologics market of the Middle East and Africa is expanding due to increasing health investments in the region, development in healthcare facilities, and greater demand for advanced therapies. More chronic diseases are being noticed in the region, including diabetic conditions, cardiovascular disease, and cancer, which is making the demand for these biologic drugs rise. The government is also investing in healthcare reforms to make access to biologics better, especially in countries like the UAE, Saudi Arabia, and South Africa. The use of biosimilars and health awareness among patients is also increasing market growth.

Key Regional Takeaways:

UNITED STATES BIOLOGICS MARKET ANALYSIS

In 2025, the United Sates accounts for 88.70% of the biologics market in North America. The adoption of advanced treatments is transforming medicine by offering more personalized treatment options in the US. Advanced therapies are now tailored to specific disease mechanisms and have resulted in outcomes that traditional methods often cannot achieve. According to HIPAA Journal, the average private healthcare spending in the U. S. is USD 11,197 per person annually (CMS, 2024), which reflects this growing trend toward personalized medicine. This movement opens high-technology avenues for biologics to satisfy a diversity of medical needs. Shifting focus toward personalized medicine has significantly improved the condition of people with chronic diseases. Innovation in R&D is bringing safer and more efficient next-generation therapies. The tie-up between service providers, who are the healthcare operators, and the biotech organizations is accelerating non-stop new technology interventions into treatment modules while ensuring an effective governance architecture that will ensure and continue to drive safety coupled with innovation. Furthermore, better support for patients is bridging the access gaps to advanced therapies and leads to better management of disease. These collaborations are sowing a rich healthcare future that continually pushes the limits of medical advancement.

ASIA PACIFIC BIOLOGICS MARKET ANALYSIS

Fast innovations in advanced medical technologies are altering the treatment paradigms and providing tailored strategies that are meeting unmet clinical needs. Initiatives in the expansion of capacity for production are making access more widespread, thus facilitating the reduction of barriers to healthcare services. Collaboration between local research institutes and international companies promotes knowledge sharing and, thus, the pace of innovation. Sensitization and training programs are significantly increasing the patient's understanding and embracing of new therapeutic interventions. Investment in the healthcare structure is opening opportunities for many, especially those in the urban areas, to have access to complex treatment modalities. According to the Ministry of Health and Family Welfare, the healthcare structure of India is aided by an increase in government health spending, reaching about USD 51 Billion in 2021-22, and an aim for public investment to increase to 2.5% of GDP by 2025, builds support for the biologics ecosystem by enhancing the ease of access to superior health facilities through initiatives like National Health Mission and Ayushman Bharat Health Infrastructure Mission. The introduction of low-cost biosimilars plays a vital role in ensuring the extension of innovative medicines, thereby ensuring diverse population groups benefit from medical innovation.

EUROPE BIOLOGICS MARKET ANALYSIS

European countries are emerging as leaders in healthcare innovation, focusing on cutting-edge research and novel medical breakthroughs. With more financial investment in biotechnology and clinical trials, the way is now becoming smooth for effective treatment options for complex health problems. Accelerations in the pace of disease management research and development resulting from collaborations between academic institutes and pharmaceutical companies have paved the way for better services to patients. Huge coverage of insurance systems and reimbursement structures make specialist care accessible as well as affordable for most of the population. This is seen in Germany; according to Germany Visa, Germany has allocated approximately $521.5 Billion toward healthcare in 2021, with over 90% of its population falling under statutory health insurance. This extensive coverage leads to a higher life expectancy and allows for significant investments in biologics focused on conditions like cancer and cardiovascular diseases. Moreover, sustainability is also becoming a priority, with green manufacturing approaches on the rise. The cross-border sharing of clinical data also supports the adoption of more advanced medical practices, leading to better healthcare delivery throughout the region.

LATIN AMERICA BIOLOGICS MARKET ANALYSIS

Advances in therapy in the field have been based on meeting local needs with specific tailored solutions, ensuring wider suitability. A greater emphasis on research and development in specific therapeutic areas helps to bring about cost-effective breakthroughs without compromising efficacy. According to the International Trade Administration, U. S. Department of Commerce, Brazil is the largest healthcare market in Latin America, with 9.47% of its GDP allocated to healthcare (USD161 Billion), which strengthens strong research and development programs that improve biologics innovation. With 427,097 hospital beds and public-private partnerships, its focus on innovation, including vaccine manufacturing and therapeutic developments, provides extensive opportunities for biologics to address chronic illnesses and prepare for pandemics. Using the latest emerging technologies, the region is able to show excellent local production capabilities, which is necessary to increase availability. Moreover, cross-industry efforts directed toward increasing knowledge-sharing and skill development create an environment that fosters transformational improvements.

MIDDLE EAST AND AFRICA BIOLOGICS MARKET ANALYSIS

Biologics are transforming the treatment landscapes as they have precision in targeting the disease mechanisms. These therapies allow for more effective and tailored interventions, particularly with complex conditions, as they focus on root causes rather than merely addressing symptoms. Their capacity to provide individualized treatments promotes better results and lower probabilities of adverse side effects, thus instilling trust among patients and health professionals. At the same time, the growing prevalence of cancer has created a demand for innovative therapies. According to the WHO, the surging cancer rates in the Arab World, with an anticipated 1.8-fold increase in incidence by 2030, underscore the escalating burden of disease. This surge presents a significant opportunity for biologics, offering advanced therapeutic solutions to confront the rising public health challenge. This shift is driven by increased awareness about early diagnosis and improved access to advanced medical treatments. With the emphasis on improving outcomes, the uptake of innovative therapies is gaining pace steadily, making it a very lively environment for enhancements in treatment protocols and patient care.

COMPETITIVE LANDSCAPE:

Increasing focus is on strategic collaborations, acquisitions, and research for improving their market positioning by players in the biologics market. They are also focusing on advancement in monoclonal antibodies, gene therapies, and cell-based therapies that have potential applications in dealing with the complexity of disease states, including cancer, autoimmune diseases, and many genetic conditions. Next-generation biologics, including bispecific antibodies and CAR-T therapies, are investments by companies to fill in unmet medical needs. Biosimilars, too, are aggressively being developed by various market players, which take advantage of patent expiries for blockbuster biologic drugs, making them cost-efficient alternatives for originators. Biologic manufacturing processes have also become optimized through advanced technologies like automation, AI, and machine learning to enhance efficiency and scalability. These strategies are expected to fuel market growth and innovation over the coming years.

The report provides a comprehensive analysis of the competitive landscape in the biologics market with detailed profiles of all major companies, including:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

Key Questions Answered in This Report

  • 1.How big is the biologics market?
  • 2.What is the future outlook of biologics market?
  • 3.What are the key factors driving the biologics market?
  • 4.Which region accounts for the largest biologics market share?
  • 5.Which are the leading companies in the global biologics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Biologics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Source

  • 6.1 Microbial
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Mammalian
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Product

  • 7.1 Monoclonal Antibodies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Vaccines
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Recombinant Proteins
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antisense, RNAi and Molecular Therapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Disease

  • 8.1 Oncology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Immunological Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cardiovascular Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Hematological Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Manufacturing

  • 9.1 Outsourced
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 In-House
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche Ltd
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 SWOT Analysis
    • 15.3.5 GlaxoSmithKline plc
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Sanofi
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Biologics Market: Major Drivers and Challenges
  • Figure 2: Global: Biologics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Biologics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Biologics Market: Breakup by Source (in %), 2025
  • Figure 5: Global: Biologics Market: Breakup by Product (in %), 2025
  • Figure 6: Global: Biologics Market: Breakup by Disease (in %), 2025
  • Figure 7: Global: Biologics Market: Breakup by Manufacturing (in %), 2025
  • Figure 8: Global: Biologics Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Biologics (Microbial) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Biologics (Microbial) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Biologics (Mammalian) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Biologics (Mammalian) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Biologics (Other Sources) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Biologics (Other Sources) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Biologics (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Biologics (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Biologics (Vaccines) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Biologics (Vaccines) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Biologics (Recombinant Proteins) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Biologics (Recombinant Proteins) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Biologics (Antisense, RNAi and Molecular Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Biologics (Other Products) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Biologics (Other Products) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Biologics (Oncology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Biologics (Oncology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Biologics (Immunological Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Biologics (Immunological Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Biologics (Cardiovascular Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Biologics (Cardiovascular Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Biologics (Hematological Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Biologics (Hematological Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Biologics (Other Diseases) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Biologics (Other Diseases) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Global: Biologics (Outsourced) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Global: Biologics (Outsourced) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Global: Biologics (In-House) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Global: Biologics (In-House) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: North America: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: North America: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: United States: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: United States: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Canada: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Canada: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Asia-Pacific: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Asia-Pacific: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: China: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: China: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Japan: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Japan: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: India: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: India: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: South Korea: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: South Korea: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Australia: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Australia: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Indonesia: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Indonesia: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Others: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Others: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Europe: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Europe: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Germany: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Germany: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: France: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: France: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: United Kingdom: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: United Kingdom: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Italy: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Italy: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Spain: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Spain: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Russia: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Russia: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Latin America: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Latin America: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Brazil: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Brazil: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Mexico: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Mexico: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 83: Others: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 84: Others: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 85: Middle East and Africa: Biologics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 86: Middle East and Africa: Biologics Market: Breakup by Country (in %), 2025
  • Figure 87: Middle East and Africa: Biologics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Global: Biologics Industry: SWOT Analysis
  • Figure 89: Global: Biologics Industry: Value Chain Analysis
  • Figure 90: Global: Biologics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Biologics Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Biologics Market Forecast: Breakup by Source (in Million USD), 2026-2034
  • Table 3: Global: Biologics Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 4: Global: Biologics Market Forecast: Breakup by Disease (in Million USD), 2026-2034
  • Table 5: Global: Biologics Market Forecast: Breakup by Manufacturing (in Million USD), 2026-2034
  • Table 6: Global: Biologics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Biologics Market: Competitive Structure
  • Table 8: Global: Biologics Market: Key Players